Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16687
Country/Region: Kenya
Year: 2017
Main Partner: Health Strat
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $1,950,977 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $52,415
Health Systems Strengthening (OHSS) $160,000
Testing: HIV Testing and Counseling (HVCT) $327,781
Sexual Prevention: Other Sexual Prevention (HVOP) $701,226
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $115,495
Treatment: Adult Treatment (HTXS) $564,232
Treatment: Pediatric Treatment (PDTX) $29,828
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 4
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 2
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 36
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 13
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 57
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 23
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 141
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 62
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 228
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 97
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 156
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 66
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 237
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 102
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 46
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 17
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 50
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2018 18
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 267
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 1,794
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 668
GEND_GBV Number of people receiving post-GBV care 2018 2,462
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2018 60,617
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 117,586
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 142
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 525
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 1,354
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 592
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 590
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 446
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 886
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 1,432
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 2,303
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 4,975
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 3,744
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 14,667
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 267
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 1,168
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative 2018 4,927
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative 2018 8,010
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative 2018 4,583
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 13,288
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 48,516
HTS_TST Sum of Test Result disaggregates 2018 5,168
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2018 2,135
HTS_TST_POS By Test Result: Positive 2018 5,168
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 18
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 141
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 17
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 145
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 203
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 577
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 774
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 32
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 75
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive 2018 358
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive 2018 150
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive 2018 94
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 908
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 1,619
PMTCT_ART Already on ART at beginning of current pregnancy 2018 263
PMTCT_ART New on ART 2018 251
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 514
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 7,470
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 514
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 348
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 154
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 12
PMTCT_STAT By Age (Numerator): 15-19 2018 519
PMTCT_STAT By Age (Numerator): 20-24 2018 1,941
PMTCT_STAT By Age (Numerator): 25-49 2018 5,010
PMTCT_STAT By Number of known positives: 15-19 2018 16
PMTCT_STAT By Number of known positives: 20-24 2018 70
PMTCT_STAT By Number of known positives: 25-49 2018 177
PMTCT_STAT By Number of new negative: 15-19 2018 486
PMTCT_STAT By Number of new negative: 20-24 2018 1,805
PMTCT_STAT By Number of new negative: 25-49 2018 4,657
PMTCT_STAT By Number of new positives: 15-19 2018 17
PMTCT_STAT By Number of new positives: 20-24 2018 66
PMTCT_STAT By Number of new positives: 25-49 2018 176
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 7,470
PMTCT_STAT_den By Age (Denominator): <15-19 2018 519
PMTCT_STAT_den By Age (Denominator): 20-24 2018 1,941
PMTCT_STAT_den By Age (Denominator): 25-49 2018 5,010
PP_PREV Age/sex: 15-19 Female 2018 441
PP_PREV Age/sex: 15-19 Male 2018 787
PP_PREV Age/sex: 20-24 Female 2018 1,155
PP_PREV Age/sex: 20-24 Male 2018 2,983
PP_PREV Age/sex: 25-49 Female 2018 7,298
PP_PREV Age/sex: 25-49 Male 2018 10,209
PP_PREV Age/sex: 50+ Female 2018 2,190
PP_PREV Age/sex: 50+ Male 2018 2,409
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 27,472
PP_PREV Sum of Age/Sex disaggregates 2018 27,472
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 79
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 277
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 360
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 360
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 3
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 79
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 277
TB_PREV By Age/Sex (Numerator): <15, Female 2018 19
TB_PREV By Age/Sex (Numerator): <15, Male 2018 15
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 671
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 837
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 1,542
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,542
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 1,711
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 21
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 16
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 747
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 927
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 1,711
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 10
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 194
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 16
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,080
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,300
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,359
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 10
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 203
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 16
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,130
TX_CURR Age/Sex: <1 2018 6
TX_CURR Age/Sex: <1-9 2018 13
TX_CURR Age/Sex: 10-14 Female 2018 41
TX_CURR Age/Sex: 10-14 Male 2018 31
TX_CURR Age/Sex: 15-19 Female 2018 186
TX_CURR Age/Sex: 15-19 Male 2018 243
TX_CURR Age/Sex: 20-24 Female 2018 743
TX_CURR Age/Sex: 20-24 Male 2018 972
TX_CURR Age/Sex: 25-49 Female 2018 746
TX_CURR Age/Sex: 25-49 Male 2018 973
TX_CURR Age/Sex: 50+ Female 2018 187
TX_CURR Age/Sex: 50+ Male 2018 243
TX_CURR Aggregated Age/Sex: <15 Female 2018 91
TX_CURR Aggregated Age/Sex: <15 Male 2018 77
TX_CURR Aggregated Age/Sex: 15+ Female 2018 2,223
TX_CURR Aggregated Age/Sex: 15+ Male 2018 2,470
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 9,245
TX_CURR Sum of age/sex disaggregates 2018 429
TX_CURR Sum of Aggregated Age/Sex <15 2018 168
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 4,693
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 4,861
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 15
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 12
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 322
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 329
TX_NEW Breastfeeding status 2018 23
TX_NEW By Age/Sex: 10-14 Female 2018 6
TX_NEW By Age/Sex: 10-14 Male 2018 5
TX_NEW By Age/Sex: 15-19 Female 2018 42
TX_NEW By Age/Sex: 15-19 Male 2018 59
TX_NEW By Age/Sex: 20-24 Female 2018 169
TX_NEW By Age/Sex: 20-24 Male 2018 239
TX_NEW By Age/Sex: 25-49 Female 2018 172
TX_NEW By Age/Sex: 25-49 Male 2018 240
TX_NEW By Age/Sex: 50+ Female 2018 43
TX_NEW By Age/Sex: 50+ Male 2018 58
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 1,711
TX_NEW People in prisons and other enclosed settings 2018 779
TX_NEW Pregnancy status 2018 208
TX_NEW Sum of Age/Sex disaggregates 2018 1,033
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 678
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 9,222
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 8,277
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 95
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 8
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 84
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 6
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 3,411
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 253
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 4,109
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 311
TX_PVLS Numerator: Indication: Routine 2018 7,699
TX_PVLS Numerator: Indication: Targeted 2018 578
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 119
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 10
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 103
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 7
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 3,794
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 282
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 4,560
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 347
TX_PVLS_den Denominator: Indication: Routine 2018 8,576
TX_PVLS_den Denominator: Indication: Targeted 2018 646
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 20
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 16
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 702
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 888
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 1,626
TX_RET Numerator by Status: Breastfeeding 2018 22
TX_RET Numerator by Status: Pregnant 2018 208
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 1,805
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 20
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 16
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 781
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 988
TX_RET_den Denominator by Status: Breastfeeding 2018 22
TX_RET_den Denominator by Status: Pregnant 2018 208
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 8,832
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 143
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 1
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 29
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 112
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 144
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 113
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 3,872
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 4,703
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 1,411
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 90
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 262
TX_TB_den Denominator: By Screen Result: Negative 2018 7,069
TX_TB_den Denominator: By Screen Result: Positive 2018 1,763
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 1,763
Cross Cutting Budget Categories and Known Amounts Total: $316,011
Gender: Gender Based Violence (GBV) $3,854
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $3,854
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Human Resources for Health $308,303